OPTIMIZATION OF TENOXICAM LOADED NIOSOMES USING QUADRATIC DESIGN
Objective: The objective of the present study was to obtain an optimized formula of Tenoxicam (TNX) niosomes using Quadratic Design.
Methods: TNX niosomes were prepared by Organic Solvent Injection method and all vehicles were evaluated for their entrapment efficiency (EE%), and Particle Size(nm).
Results: EE% was found to be between 77.88 and 89.98. Percentage entrapment efficiency was significantly affected by the applied processing variables such as the concentration of span 60 as well as cholesterol. The mean vesicle size of drug loaded niosomes of the different batches ranged between 79-190 nm. Vesicle size of drug loaded niosomal batches was found to decrease as the concentration of span increases. The effects of all the tested independent variables have P-values<0.05.
Conclusion: Quadratic design succeeded in the optimization of the formulation ingredients on EE% and particle size of Tenoxicam niosomes. Finally the optimization process provides a formula having the optimum level of factors.Keywords: Quadratic Design, Entrapment efficiency (EE%), Niosomes, Optimization, Tenoxicam (TNX).
2. Fathy IA, Dawaba HM, Mansour A, Samy AM. Evaluations of the anti-inflammatory and analgesic effects of piroxicam are loaded microemulsion in topical formulations. Int J Pharm Pharm Sci 2011;3:66-70.
3. Gareth A. Encyclopedia of Pharmaceutical Technology, Marcel Dekker, Inc., New York; 2002. p. 1922-37.
4. Cochran WG, Cox GM. Experimental designs. 2nd ed. New York; 1992. p. 335-9.
5. Dsai S, Doke A, Disouza J, Athawale R. Development and evaluation of antifungal topical niosomal gel formulation. Int J Pharm Pharm Sci 2011;3:224-31.
6. Higuchi T. Mechanism of sustained-action medication: theoretical analysis of the rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1993;52:1145-8.
7. Box GE, Hunter WG, Hunter JS. In: "Statistics for experiments: design with more than one blocking variable", John Wiley and sons. New York; 1978. p. 245-80.
8. Gulati M, Grover M, Singh M. Lipophilic drug derivatives in liposomes. Int J Pharm 2002;165:129â€“68.
9. Abd-Elbary A, El-laithy HM, Tadros MI. Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium. Int J Pharm 2008;357:189â€“98.
10. Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int J Pharm 2007;328:130â€“41.
11. Singh CH, Jain CP, Kumar BN. Formulation, characterization, stability and in vitro evaluation of nimesulide niosomes. Pharmacophore 2011;2:168-85.
12. Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Controlled Release 1998;54;149â€“65.
13. LÂ´opez JM, GonzÂ´alez ML, Rabasco AM. Effect of cholesterol and ethanol on dermal delivery from DPPC liposomes. Int J Pharm 2005;298:1â€“12.
14. Guinedi AS, Mortada ND, Mansour S, Hathout RM. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm 2005;306:71â€“82.